Brokerages forecast that Zimmer Biomet Holdings Inc (NYSE:ZBH) will report $1.88 earnings per share for the current fiscal quarter, according to Zacks. Ten analysts have provided estimates for Zimmer Biomet’s earnings, with estimates ranging from $1.85 to $1.90. Zimmer Biomet posted earnings per share of $2.13 in the same quarter last year, which would suggest a negative year over year growth rate of 11.7%. The business is expected to report its next earnings report on Thursday, April 26th.
According to Zacks, analysts expect that Zimmer Biomet will report full-year earnings of $7.80 per share for the current year, with EPS estimates ranging from $7.68 to $8.25. For the next year, analysts expect that the company will report earnings of $8.37 per share, with EPS estimates ranging from $8.00 to $9.05. Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Zimmer Biomet.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.10. The business had revenue of $2.07 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.14 EPS.
Zimmer Biomet (ZBH) traded down $3.94 on Friday, hitting $107.44. The company had a trading volume of 2,511,942 shares, compared to its average volume of 1,340,260. The firm has a market cap of $23,235.94, a PE ratio of 11.92, a P/E/G ratio of 1.99 and a beta of 1.13. The company has a current ratio of 1.50, a quick ratio of 0.81 and a debt-to-equity ratio of 0.76. Zimmer Biomet has a 1-year low of $107.32 and a 1-year high of $133.49.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. The ex-dividend date of this dividend is Wednesday, March 28th. Zimmer Biomet’s dividend payout ratio (DPR) is 10.65%.
In other news, VP Chad F. Phipps sold 20,826 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $115.95, for a total transaction of $2,414,774.70. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Bryan C. Hanson acquired 25,077 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $119.68 per share, for a total transaction of $3,001,215.36. The disclosure for this purchase can be found here. 1.07% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of the company. Private Advisor Group LLC raised its position in shares of Zimmer Biomet by 18.6% in the 3rd quarter. Private Advisor Group LLC now owns 6,733 shares of the medical equipment provider’s stock worth $791,000 after buying an additional 1,057 shares during the period. Jana Partners LLC raised its position in shares of Zimmer Biomet by 16.6% in the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Zimmer Biomet by 10.0% in the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 16,444 shares of the medical equipment provider’s stock worth $1,925,000 after buying an additional 1,494 shares during the period. WINTON GROUP Ltd purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth $370,000. Finally, Cipher Capital LP purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth $1,225,000. Institutional investors and hedge funds own 86.49% of the company’s stock.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.